Progress in Vaccination against Cancer (PIVAC) aims to bring together translational and clinical oncologists and immunologists dealing with active vaccination against cancer for three days of presentations on the most recent advances in the field. Besides providing an up-to-date overview of many aspects of tumour immunology, thanks to its friendly atmosphere and the limited number (max 100) of participants, PIVAC fosters a lively and fruitful discussion, promoting interactions between participants, speakers and companies attending the conference and encouraging the emergence of new partnerships.

Background

The exploitation of the immune system to fight tumours has huge potential, but it still represents a challenge to be overcome. New information has been recently gathered on: the role of the tumour microenvironment as a major factor in determining the immunotherapy outcome; the exploitation of comparative oncology to predict immunotherapy effectiveness; and the potentialities of various vaccination strategies. Moreover, initial positive clinical results are becoming apparent. These new acquisitions will be the focus of PIVAC 14.

Who should attend?

PIVAC is dedicated to scientists working on active immunisation against cancer, both in prevention and therapy, at the pre-clinical and/or clinical level. PIVAC is also an ideal environment to stimulate the interest of students and young researchers who approach this field of research

Topics to be covered in the conference include:

Microenvironment
Comparative oncology
Peptide-based vaccines
DNA-based vaccines
ACT (adoptive cell therapy)
Electrotransfer